Aurora Board Unanimously Rejects Curaleaf's $4.00 Hostile Bid, Citing Undervaluation and Debt Risks
ACB sits 57% above its 52-week low of $2.56.
Summary
Aurora's board unanimously recommends shareholders reject Curaleaf's hostile bid, filing a Directors' Circular that details why the $4.00 per share offer is inadequate. The company highlights its debt-free balance sheet with $149M in cash versus Curaleaf's over $1B in debt, arguing the bid would use Aurora's own cash to fix Curaleaf's balance sheet. Aurora also warns that shareholders would own only 7.7% of the combined company but hold just 3.2% of votes, significantly weakening their influence. Independent analysts from TD Securities support the view that the bid undervalues Aurora. This formal rejection follows the initial bid announcement on August 11 and Aurora's earlier rebuttals, escalating the takeover battle. The board's unanimous stance and detailed circular are likely to harden shareholder resistance, but the outcome now depends on whether Curaleaf raises its offer or shareholders tender despite the recommendation.
At the time of this announcement, ACB was trading at $4.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $262.6M. The 52-week trading range was $2.56 to $6.67. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.